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Prostate cancer (PCa) remains an important public health concern in Wes-
tern countries. Metabolic syndrome (MeS) is a cluster of pathophysiologi-
cal disorders with increasing prevalence in the general population that is a
risk factor for PCa. Several studies have determined that a crosstalk
between white adipose tissue (WAT) and solid tumors favors cancer aggres-
siveness. In this work, our main goal was to investigate the interaction
between WAT and PCa cells through microRNAs (miRNAs), in MeS mice.
We developed a MeS-like disease model using C57BL/6J mice chronically
fed with high-fat diet (HFD) that were inoculated with TRAMP-C1 PCa
cells. A group of five miRNAs (mmu-miR-221-3p, 27a-3p, 34a-5p, 138-5p,
and 146a-5p) were increased in gonadal WAT (gWAT), tumors, and
plasma of MeS mice compared to control animals. Three of these five miR-
NAs were detected in the media from gWAT and TRAMP-C1 cell cocul-
tures, and significantly increased in MeS context. More importantly, hsa-
miR-221-3p, 146a-5p, and 27a-3p were increased in bloodstream of PCa
patients compared to healthy donors. Using miRNA microarrays, we
found that 121 miRNAs were differentially released to the coculture media
between HFD-gWAT and tumor cells compared to control diet-gWAT and
tumor cells. Target genes for the 66 most deregulated miRNAs were
involved in common pathways, mainly related to fatty acid metabolism,
ER protein processing, amino acid degradation, PI3K AKT signaling, and
PCa. Our findings show for the first time a signature of five miRNAs as
important players involved in the interaction between WAT and PCa in
MeS mice. Further research will be necessary to track these miRNAs in the
interaction between these tissues as well as their role in PCa patients with
MeS.
Abbreviations
BPH, benign prostatic hyperplasia; CD, control diet; CTBP1, C-terminal binding protein 1; gWAT, gonadal white adipose tissue; HD, healthy
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1. Introduction
Prostate cancer (PCa) is still the most prevalent cancer
among men and the fifth cause of death by cancer
worldwide [1]. Metabolic syndrome (MeS) is a disease
whose diagnosis includes alteration of at least three of
the following factors: visceral adiposity, triglycerides,
high-density lipoprotein levels, hypertension, and fast-
ing glucose levels [2]. Several epidemiological studies
have determined a significant correlation associating
MeS with more aggressive PCa tumors and recurrence
[3]. Nonetheless, the molecular mechanism responsible
for the effect of MeS on PCa development is yet to be
fully determined.
Our group identified C-terminal binding protein 1
(CTBP1), a transcriptional corepressor, as a molecular
link associating PCa and MeS. We previously gener-
ated a PCa and MeS-like disease model by chronically
feeding mice with a high-fat diet (HFD). Thus, we
identified novel pathways regulated by CTBP1 on a
MeS environment [4,5]. CTBP1 depletion in androgen-
insensitive PCa xenografts from HFD-fed mice affects
the expression of genes and microRNAs (miRNAs)
involved in hormone biosynthesis, olfactory signaling,
and cell adhesion pathways, impacting in PCa develop-
ment and progression [6–8]. Additionally, an andro-
gen-sensitive PCa and MeS-like mice model allowed us
to determine that MeS significantly increased tumor
growth. Compared to control diet (CD), HFD-fed
mice showed high amount of white adipose tissue
(WAT), adipocyte size, and macrophage infiltration,
with adipogenesis and inflammation-related genes
expression induction, which indicates chronic WAT
inflammation, an important feature of MeS. Addition-
ally, cocultures of androgen-sensitive PCa cells with
WAT determined that WAT from HFD-fed mice
induced proliferation and expression of oncogenes in
PCa cells [7].
miRNAs are small noncoding RNAs (18–22 nts
long) that target mRNA to reduce protein expression
[9]. It was reported that miRNAs are important for
WAT function regulating adipogenesis, metabolism,
and signaling pathways [10], and probably released by
WAT [10,11]. Numerous studies have reported the role
of miRNAs in cancer, including PCa [12]. It was
reported that tumors release miRNAs into the blood-
stream at different stages of the disease [12].
Several studies have determined that a crosstalk
between WAT and solid tumors favors cancer aggres-
siveness. Mature adipocytes provide adipokines, hor-
mones, and lipids to cancer cells, while stromal and
immune cells from WAT locally secrete paracrine
factors within the tumor microenvironment [13]. More-
over, it was suggested that in breast cancer, miRNAs
from adipocytes gave rise to a niche from which,
under aberrant conditions, a neoplastic transformation
of breast cells may start [14]. Few studies investigated
the interaction between WAT and PCa cells in a MeS
microenvironment [15,16]. In this work, our main goal
was to explore the interaction between WAT and PCa
cells through miRNAs in MeS mice.
2. Materials and methods
2.1. Cell culture and treatments
TRAMP-C1 cell line (ATCC: CRL-2730, Manassas,
VA, USA) was grown in DMEM medium (GIBCO,
Thermo Scientific, Beverly, MA, USA) supplemented
with 10% of FBS, antibiotics, and 250 IUμL−1 of
human recombinant insulin.
2.2. Immunocompetent PCa allografts and MeS
murine model
Four-week-old C57BL/6J male mice (N = 16) were
housed under pathogen-free conditions following the
IBYME’s animal care guidelines. Mice were random-
ized into two dietary groups and fed ad libitum during
27 weeks with CD (3120 kcalkg−1, 5% fat) or HFD
(4520 kcalkg−1, 37% fat). After 15 weeks of diet, mice
were injected s.c. with TRAMP-C1 (3 × 106) cell line.
Animals were sacrificed in the 27th week, and tumor,
WAT, and blood samples were collected. The meta-
bolic state of the animals and tumor volume was pre-
viously reported [7].
2.3. Ex vivo coculture of gWAT with TRAMP-C1
cells
TRAMP-C1 cells were cocultured in 24-Transwell
plates with gWAT obtained from CD or HFD mice as
previously described [7]. Briefly, TRAMP-C1 cells were
seeded in DMEM complete medium at a density of
1.5 × 104 cells/well. After 24 h, medium was refreshed
and 150 mg of gWAT obtained from CD or HFD
C57BL/6J mice was placed onto cell-culture inserts
(3.0 μm pore size, high-density membrane) in M199
(Sigma-Aldrich, Darmstadt, Germany) complete med-
ium for 48 h. Then, TRAMP-C1 cells and gWAT were
collected in TriReagent (Molecular Research Center,
Cincinnati, OH, USA) for RNA isolation and RT–-
qPCR. Culture medium was collected for RNA
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isolation followed by miRNA microarray hybridiza-
tion or RT–qPCR. As a control, TRAMP-C1 cells
were cultured without the addition of gWAT.
2.4. RNA isolation and reverse transcription (RT)
Total RNA from cells, allografts, WAT, or plasma
was isolated using TriReagent (Molecular Research
Center, Cincinnati, OH, USA). For plasma samples,
cel-miR-39 synthetic miRNA (20–40 fmol) was spiked
in before RNA isolation. miRNAs were retrotran-
scribed using the stem-loop method as previously
described [8,17]. For RT, 100 ng (cells, allografts or
WAT) or 4 μL (plasma o culture medium) of total
RNA and 0.07 μM of stem-loop primer were preheated
(70 °C, 5 min). RT was performed using M-MLV
reverse transcriptase (Promega, Madison, WI, USA)
and incubated in MyGenie96 Thermal Block (Bioneer,
Daedeok-gu, Daejeon, Republic of Korea) (30 min
16 °C, 50 min 37 °C, 15 min 70 °C).
2.5. Primer design for stem-loop RT–qPCR
Primer design for stem-loop RT–qPCR was performed
following the guidelines described in Chen et al. work
[17] and summarized at Table S1. Briefly, miRNA
mature sequence was downloaded from miRBase data-
base (http://www.mirbase.org/). The stem-loop primer
for RT was designed using a stem-loop sequence
(GTCTCCTCTGGTGCAGGGTCCGAGGTATTCG-
CACCAGAGGAGAC) followed by the last six
nucleotides from the 50 end of the mature miRNA.
Forward primer for qPCR was designed using the
mature sequence of the miRNA without the last six
bases of the 50 end. To extend the sequence, we added
a short sequence formed by C and G to the 50 end
(e.g., CGCGCG). Likewise, the universal reverse pri-
mer was designed to match to the stem-loop sequence.
Tm, self-complementarity, and off target products
were assessed using the primer blast tool (https://www.
ncbi.nlm.nih.gov/tools/primer-blast/). As exclusion cri-
teria, we chose primer pairs with an optimal Tm 60 °C
with 5 °C range and self-complementarity and self-30
complementarity less than 4. For all primer pairs, the
amplification efficiency was calculated and ranged
between 90% and 105% which are adequate for rela-
tive quantification of expression by RT–qPCR using
ΔΔCT method.
2.6. Real-time PCR analysis
Tumors, cells and gWAT qPCRs were performed in
25 μL with 0.05–1 μL RT product, 1 U Taq DNA
polymerase (Pegasus), 4 mM MgCl2, 0.2 mM dNTPs,
3 × 10−5 μL SYBR Green (Sigma-Aldrich), 0.1 μM for-
ward primer, and 0.1 μM reverse primer. The reactions
were incubated in StepOne Plus Real Time PCR
(Applied Biosystems, Beverly, MA, USA) (94 °C
2 min, 40 cycles: 95 °C 15 s, annealing temperature
20 s, 72 °C 25 s and 95 °C 15 s). Plasma and media
qPCRs were run in 10 μL with 0.1 μM of each primer
and 5 μL of PowerUp™ SYBR™ Green Master Mix
(Thermo Fisher, Beverly, MA, USA), in StepOne Plus
Real Time PCR (Applied Biosystems, Beverly, MA,
USA) (50 °C 2min, 95 °C 10 min, 40 cycles: 95 °C
15 s, annealing temperature 15 s, 60 °C 1 min, and
95 °C 15 s). The expression levels of miRNAs were
calculated using ΔΔCT method normalizing to geomet-
ric mean of mmu-miR-103a-3p and 191-5p and control
(for tumor, cells, and gWAT). The expression levels of
plasma were normalized to cel-miR-39 (a synthetic
spike in added to the sample prior to RNA extrac-
tion). For culture media, we used mmu-miR-19b as a
normalizer since it was detected with high signal in the
microarray analyses and showed no changes between
the experimental groups. Primer sequences are listed in
Table S1.
2.7. Microarray analysis
RNA from coculture medium between TRAMP-C1
cells and gWAT from CD and HFD-fed mice was iso-
lated with NucleoSpin® miRNA Plasma (Macherey-
Nagel, Düren, Germany) kit and hybridized with
GeneChip® miRNA 4.0 Array (Affymetrix, Santa
Clara, CA, USA) (N = 2 per group). For miRNA
expression analysis, we employed the Limma and
pd.mirna.4.0 packages in the R/BIOCONDUCTOR (Roswell
Park Comprehensive Cancer Center, Buffalo, NY,
USA) environment. Firstly, CEL files were uploaded
into R; to read and normalize the data, we used the
gcrma package, while for annotation, we used the
pd.mirna.4.0 package. The gcrma function adjusts for
background intensities which include optical noise and
nonspecific binding. gcrma converts background
adjusted probe intensities to expression measures using
the same normalization and summarization methods
as rma (Robust Multiarray Average), in which raw
intensity values are background corrected, log2 trans-
formed, and then quantile normalized. For differential
expression analysis, we used the rank product method
for two-class unpaired data and an alpha critical P
value of 0.01 [18]. For miRNA pathway analysis, a list
of experimentally validated target genes miRNA,
derived from DIANA-TARBASE v7 (DIANA LAB,
University of Thessaly, Filellinon, Volos, Greece), was
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obtained with the DIANA-MIRPATH v3tool (DIANA
LAB, University of Thessaly) for DE miRNAs
(LogFC > 1, P value > 0.01). Functional enrichment
analysis of target genes was performed with the
ClueGo plug-in of the CYTOSCAPE software [19] in order
to capture the biological processes associated with DE
miRNAs.
2.8. TCGA dataset analysis
MiRNA expression of prostate tumors of patients was
obtained from the TCGA Prostate Cancer (PRAD)
cohort using UCSC XENA resource (http://xena.ucsc.edu/)
[20]. Fifty-two PCa samples and 52 normal adjacent tis-
sues (NAT) were included in the present study exclud-
ing patients without this information. Clinical-
pathological (e.g., age, risk category) and survival data
(overall and event-free survival) for these patients were
obtained using the R package ggpubr (clinical-pathologi-
cal data of patients are in Table S2). For miRNA
mature strand expression, the miRNA-Seq (Illu-
minaHiSeq_miRNASeq) data were downloaded as log2
(RPM + 1) values. For statistical analysis, normality of
data was assessed using Shapiro–Wilk test and homo-
geneity of variances was analyzed by boxplot. If data
fulfill the requirements, a paired sample t-test was used.
Otherwise, Sign Median test was performed using sing-
median.test R package. The results shown here are in
whole based upon data generated by the TCGA
Research Network: https://www.cancer.gov/tcga.
2.9. Circulating miRNA profile analysis
Circulating miRNA expression profile was analyzed in
the plasma of a cohort of 60 PCa patients and 78 con-
trols [51 men with benign prostatic hyperplasia (BPH)
or 27 healthy donors (HD)] using microarray data
available from Mello-Grand et al. [21]. Average nor-
malized log2Intensities data (GSE113234) was down-
loaded from the Gene Expression Omnibus (GEO)
public functional genomic data repository (https://
www.ncbi.nlm.nih.gov/geo/) and analyzed using the
ggpubr R package. To compare data between PCa and
non-PCa, one-way analysis of variance (one-way
ANOVA) with Tukey’s multiple comparisons test was
applied. GSE113234 was generated by Agilent
Technologies-Human miR Microarray version 19 (Agi-
lent Technologies, Santa Clara, CA, USA).
2.10. Statistical analysis
For the in vivo (N = 8 per group) and the ex vivo
experiments (N = 3 per group), the results are given as
mean and standard deviation (SD) or standard error
of the mean (SEM). For statistical analysis, normality
and homogeneity of variances were assessed using
Shapiro–Wilk and Levene tests, respectively. If data
fulfill the requirements, Student’s t-test or one-way
ANOVA followed by Tukey was used. Significance
level of 5%.
3. Results
3.1. MeS modulates miRNA expression in gWAT
from mice
Previously, we reported that MeS significantly increased
TRAMP-C1 tumor growth and oncogene expression in
C57BL/6J mice chronically fed with HFD. Additionally,
MeS mice showed altered morphology and increased
amount of WAT, with adipogenesis/inflammation gene
expression induction [7]. Here, we investigated the effect
of MeS on miRNA expression profile from gWAT.
Based on the literature, we selected 10 miRNAs
involved in adipogenesis regulation and adipocyte meta-
bolism that were reported as deregulated in obesity or
involved in adipocyte differentiation detailed in Fig. 1A.
We measured the expression of these miRNAs in the
gWAT derived from HFD and CD mice. Results
showed significantly increase in the expression of mmu-
miR-221-3p, 27a-3p, 34a-5p, 155-5p, 138-5p, and 146a-
5p, and decrease in mmu-miR-196a-5p and 143-3p levels
in HFD-gWAT compared to CD mice (Fig. 1B). No
changes were detected in mmu-miR-125b-5p and 140-5p
expression levels (Fig. 1B).
3.2. MeS induces oncomiR expression in
androgen-sensitive murine prostate tumors
We determined the expression levels of the selected
miRNAs in TRAMP-C1 tumors developed in HFD-
Fig. 1. MeS modifies the expression of miRNAs in gWAT and androgen-sensitive prostate tumors from mice. (A) Table showing a list of
miRNAs involved in adipogenesis regulation and adipocyte metabolism selected from literature. Stem-loop RT–qPCR from gWAT (B) and
TRAMP-C1 allografts (C) obtained from CD- or HFD-fed C57BL/6J mice using specific primers for the indicated miRNAs is shown (N = 8 per
group). Data were normalized to geometric mean of miR-191-5p and miR-103a-3p and control and expressed as mean and SD. Statistical
analysis was performed using two-sided t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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miRNA Accession Mature sequence Reference
mmu-miR-221-3p MIMAT0000669 agcuacauugucugcuggguuuc F.J.Ortega et al. 2010, J A. Meerson et al. (2013)
mmu-miR-27a-3p MIMAT0000537 uucacaguggcuaaguuccgc Q.Lin et al. 2009, S.Y. Kim et al. (2010)
mmu-miR-34a-5p MIMAT0000542 uggcagugucuuagcugguugu C.A. Lavery et al. (2016)
mmu-miR-155-5p MIMAT0000165 uuaaugcuaauugugauaggggu E. Karkeni et al. (2016)
mmu-miR-138-5p MIMAT0000150 agcugguguugugaaucaggccg Z. Yang et al. (2011)
mmu-miR-146a-5p MIMAT0000158 ugagaacugaauuccauggguu D. Wu et al. (2016)
mmu-miR-143-3p MIMAT0000247 ugagaugaagcacuguagcuc H. Xie et al. (2009), C. Esau et al. 2004, R. Takanabe et al.  (2008)
mmu-miR-125b-5p MIMAT0000136 ucccugagacccuaacuuguga D. Rockstroh et al. (2016)
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and CD-fed mice. Most of the miRNAs altered in
gWAT were induced in TRAMP-C1 allografts from
HFD-fed mice (mmu-miR-221-3p, 27a-3p, 34a-5p,
138-5p, 146a-5p, and 143-3p) compared to CD-fed
mice (Fig. 1C). No significant changes were observed
in mmu-miR-155-5p, 196a-5p, 125b-5p, and 140-5p
expression between diet groups.
3.3. MeS increases mmu-miR-221-3p, 27a-3p,
34a-5p, 138-5p, and 146a-5p in mice bloodstream
miRNAs are secreted as stabilized factors into the
bloodstream, as circulating miRNAs, and function as
endocrine messengers given their release and uptake by
recipient tissues throughout the body [11]. We hypoth-
esized that miRNA expression increased in tumors
might be due to the release of miRNAs from gWAT
into bloodstream, which might be uptaken by distant
PCa cells. Therefore, we isolated the total miRNAs
from HFD and CD mice plasma and measured those
that were altered in gWAT and tumors. We found that
five miRNAs: mmu-miR-221-3p, 27a-3p, 34a-5p, 146a-
5p, and 138-5p were increased in plasma from HFD-
fed mice compared to control animals (Fig. 2). These
findings indicate that these miRNAs not only circulate
in mice blood but also have a distinctive circulation
level in a MeS context.
3.4. gWAT from MeS mice releases miRNAs that
might impact on PCa growth
We previously reported that gWAT from HFD-fed
mice cocultured with TRAMP-C1 cells induced prolif-
eration and oncogene expression compared to CD-
gWAT [7]. Here, we performed an ex vivo coculture
assay, in which TRAMP-C1 cells were cocultured with
gWAT from CD- or HFD-fed mice. TRAMP-C1 cells
cultured without gWAT were used as control. After
48 h, TRAMP-C1 cells, gWAT, and coculture media
were harvested and RT–qPCR was performed. Inter-
estingly, we found that gWAT from HFD-fed mice
increased the levels of mmu-miR-221-3p, 27a-3p, 34a-
5p, 138-5p, and 146a-5p in TRAMP-C1 cells (Fig. 3
A), reproducing the same effect observed in the allo-
grafts from HFD-fed mice (Fig. 1B). Likewise, gWAT
from HFD-fed mice showed mmu-miR-221-3p, 27a-3p,
34a-5p, 138-5p, and 146a-5p expression induction,
mmu-miR-196a-5p and 143-3p repression levels and
no changes for mmu-miR-155-5p and 125b-5p com-
pared to CD mice (Fig. 3B). Moreover, mmu-miR-
221-3p, 34a-5p, and 146a-5p were released to the
coculture medium and significantly increased in the
interaction between HFD-gWAT/TRAMP-C1 cells
compared to CD-gWAT/TRAMP-C1 cells (Fig. 3C).




















































Fig. 2. MeS increases miRNA circulation in plasma from mice. Mouse plasma samples were analyzed by stem-loop RT–qPCR for the
indicated miRNAs and normalized to spike in cel-39 synthetic miRNA (N = 8 per group). 2ΔC t is graphed (ΔC t value¼C tsample C tcel39 ) and
expressed as mean and SEM. Data were analyzed by one-sided t-test.
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between WAT and PCa cells, through miRNA release,
in MeS mice.
3.5. Crosstalk between gWAT and PCa cells by
miRNA release from MeS mice
Results described above would indicate a differential
release of miRNAs, depending on whether tumor cells
are cocultured with CD of HFD-gWAT. To further
understand the differential release of miRNAs, we
conducted a miRNA microarray analysis with miR-
NAs isolated from the coculture medium between
TRAMP-C1 cells with HFD-gWAT versus TRAMP-
C1 cells with CD-gWAT.
The analysis showed a total of 121 miRNAs identi-
fied as differentially abundant. Fifty-seven of these
miRNAs showed an increase in coculture medium of
HFD compared with CD group, while 64 showed a
decrease (Fig. 4, Table S3). As shown in the volcano
plot, three groups of miRNAs based on statistical sig-
nificance versus magnitude of change were established:
Log FC > 1.5, P value < 0.01 (green, n = 20);
LogFC > 1, P value < 0.01 (yellow, n = 46); and P
value < 0.01 (red, n = 55) (Fig. 4A, Table S3). We
searched whether any of the 10 miRNAs selected
according to the literature (Fig. 1A) were among the
deregulated ones. Interestingly, we found four of them,
mmu-miR-221-3p and 146a-5p, among the upregulated
in HFD, in the groups yellow and red, respectively;
and mmu-miR-27a-3p and 125b-5p in the groups yel-
low and red of the downregulated, respectively (Fig. 4
B,C), which supports the relevance of these miRNAs
in the interaction between WAT and PCa cells in a
MeS environment.
To explore the functional role of the differentially
abundant miRNAs and identify controlled pathways,
we used DIANA-MIRPATH v3 tool. Since each miRNA
can control up to dozens of genes, we selected only the
most deregulated miRNAs—the green and orange
zones (n = 66; Fig. 4B)—to obtain a more robust
result. In addition, we employed DIANA-TARBASE v7 of
the miRPath tool, which is a reference database of
experimentally supported miRNA targets. Seventeen
of the downmodulated (17/40) and 13 of the upmodu-
lated miRNAs (13/26) showed validated target genes
(Table S4). For each group of genes, KEGG signaling
pathways were identified with a P value < 0.01 (Fig. 5,
Tables S5 and S6). Target genes of both down- and
upmodulated miRNAs shared common KEGG path-
ways, mainly related to fatty acid metabolism, ER pro-
tein processing, amino acids degradation, PI3K AKT
signaling, and PCa (Fig. 5A,B). Both lists of genes also
showed their particular pathways: Those derived from
downmodulated miRNAs enriched processes associ-
ated with Cell cycle, FoXO signaling, Hippo signaling,
and other cancer-related pathways (Fig. 5A), while
those derived from up-miRNAs were more associated
with processes related to lipid and steroid biosynthesis
and metabolic pathways (Fig. 5B). Redundancy
obtained means that different miRNAs can have the
same target, or different targets can belong to the
same pathway. Therefore, we subtracted the common
genes to both lists and performed a new functional
enrichment (Tables S7–S9). Interestingly, we observed
that targets of downmodulated miRNAs were prefer-
entially associated with cancer processes and related
pathways (P < 0.001; Fig. 5C), whereas upmodulated
miRNAs showed enrichment in specific metabolic
pathways (P < 0.001; Fig. 5D).
Overall, miRNAs obtained from the coculture med-
ium modulate a large repertoire of genes that affect
the functionality of specific metabolic and cancer-re-
lated pathways.
3.6. hsa-miR-221-3p, 27a-3p, 146a-5p, and 140-5p
are increased in bloodstream of PCa patients
Since the discovery of miRNAs, many research groups
have analyzed cancer patient blood samples in hopes
of establishing novel biomarkers of this disease. In this
sense, Mello-Grand group performed a miRNA
expression profile in 130 PCa patients, benign prostate
hyperplasia (BPH) and HD blood samples using
microarray technologies. As most of the miRNAs
from mouse can be found in humans with similar
function, in this work, we used the microarray results
available from Mello-Grand work to explore the
expression of the selected miRNAs from Fig. 1 in
plasma samples of a cohort of 60 PCa and 70 HD +
BPH patients. Our analysis evidenced that hsa-miR-
221-3p, 146a-5p, and 140-5p were increased in blood-
stream of PCa patients compared to HD but not with
BPH subjects (Fig. 6A). Moreover, hsa-miR-27a-3p
was upregulated in PCa samples compared to HD and
BPH samples (Fig. 6A), suggesting that this miRNA
would be useful to distinguish not only PCa patients
from HD, but also PCa patients from BPH individu-
als.
3.7. miRNAs deregulated in prostate tumors
from patients
In order to further understand the pattern of expres-
sion of miRNAs between plasma and tumors, we per-
formed a bioinformatical analysis using UCSC XENA
resource to determine the expression of the selected
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miRNAs (Fig. 1A) in prostate tumors respect to NAT.
As shown in Fig. 6B, we found hsa-miR-34a-5p, 155-
5p, 125b-5p, and 140-5p significantly overexpressed
and hsa-miR-221-3p, 196a-5p, and 143-3p significantly
downregulated in PCa compared to NAT (Fig. 6B).
Moreover, we did not find expression data for hsa-
miR-138-5p, and hsa-miR-27a-3p and 146a-5p showed
no changes when we compared PCa tissue and NAT.
4. Discussion
In this work, we provide evidence of a striking cross-
talk between WAT and androgen-sensitive PCa,
through miRNAs in MeS mice. We found that MeS
modulates the expression of several miRNAs in pros-
tate tumors and gWAT implicated in cancer develop-
ment and progression. In particular, we found a group
of 5 miRNAs (mmu-miR-221-3p, 27a-3p, 34a-5p, 138-
5p, and 146a-5p) that were increased in gWAT,
tumors, and plasma of MeS mice compared to control
animals (Fig. 7). Interestingly, three of these five miR-
NAs were also detected in the media from gWAT and
TRAMP-C1 cell cocultures, and significantly increased
in MeS context (Fig. 7).
To better understand the scope of these findings, we
analyzed the expression of the selected miRNAs
(Fig. 1A) in human datasets. We found that three of
the five miRNAs regulated in mice (hsa-miR-221-3p,
146a-5p, and 27a-3p) were increased in blood of PCa
patients compared to HD. Moreover, from these, only
hsa-miR-221-3p and 34a-5p were identified as deregu-
lated in PCa samples. These results indicate that at
least miR-221-3p, 146a-5p, and 27a-3p, detected in
mice, were also high in bloodstream of PCa patients.
However, of these three miRNAs, only hsa-miR-221-
3p was found to be inversely deregulated in PCa com-
pared to normal tissues, which demonstrate that the
expression of miRNAs in tumors does not always cor-
relate with their expression in bloodstream. Similarly,
Zedan et al. [22] reported that miR-221-3p is downreg-
ulated in primary metastatic prostate cancer (mPCa)
tissue and upregulated in plasma from mPCa patients
compared to the control cohort. Although these results
seem to be contradictory, it is important to highlight
that neither the source nor the mechanism of miRNAs
released into the extracellular environment or body flu-
ids is completely understood. There are several
hypotheses to explain the source of circulating miR-
NAs: passive release of free miRNAs, as a part of
ribonucleoprotein complexes (bound to proteins of the
Ago family) within apoptotic bodies or inside
microvesicles or exosomes [23]. Also, it has been pro-
posed that extracellular miRNAs can be generated
from immune cells in the tumor microenvironment
[24,25]. In this context, it would be interesting to
investigate whether the expression pattern of the pro-
posed miRNAs in this study in PCa tumors correlates
with miRNA expression in vesicles or Ago bound in
plasma or serum.
Different studies showed the expression and function
of mmu-miR-221-3p, 27a-3p, 34a-5p, 138-5p, and
146a-5p in WAT in MeS environment: For instance,
mmu-miR-221-3p and 146a expression was increased
in gWAT from HFD-fed mice [26–30]; mmu-miR-146a
controls inflammation and prevents obesity onset when
mice are fed a HFD [31] and hsa-miR-221-3p con-
tributes insulin resistance development that typically
correlates with obesity [28,29]; hsa-miR-34a-5p expres-
sion was increased during adipogenesis and associated
with high body weight index [29]; and hsa-miR-138
expression is diminished during adipocyte differentia-
tion [32].
The miRNA 221 is one of the most promising
biomarkers for PCa diagnosis and prognosis. It is
induced in PC3 cells and trigger clonogenicity of this
cell line [33,34] and in vivo growth of androgen-sensi-
tive LNCaP cells [34]. While experimental models
establish to hsa-miR-221 as an oncomiR, studies on
patient samples showed contradictory results. Similar
to our findings, some studies indicate that hsa-miR-
221-3p is decreased in PCa in comparison with normal
samples [35–37]. However, other reports showed that
Fig. 3. gWAT from MeS mice releases miRNAs impacting in prostate tumor growth. (A) Stem-loop RT–qPCR from TRAMP-C1 cells
obtained from the coculture using specific primers for the indicated miRNAs. Data were normalized to geometric mean of miR-191-5p and
miR-103a-3p and control (TRAMP-C1 cells without the addition of gWAT) and represent mean and SD of three independent experiments
with three replicates. Data were analyzed by one-way ANOVA followed by Tukey’s. (B) Stem-loop RT–qPCR from gWAT obtained from the
coculture. Data were normalized to geometric mean of miR-191-5p and miR-103a-3p and to CD group. Data were analyzed by two-sided t-
test. (C) Stem-loop RT–qPCR in culture medium from cocultures using primers specific for the indicated miRNAs. 2ΔC t is graphed. Data
were normalized to mmu-miR-19b (ΔC t value¼C tsample C tmiR19b ) and control (TRAMP-C1 cells without the addition of gWAT) and
represent the mean and SD of three independent experiments with three replicates. Data were analyzed by one-way ANOVA followed by
Tukey’s. ND: not detectable. *P < 0.05; **P < 0.01; ***P < 0.001. White bar corresponds to the group of TRAMP-C1 without the addition
of gWAT, pink bar corresponds to the TRAMP-C1 cell culture with gWAT from CD mice, and red bar corresponds to TRAMP-C1 cultured
with gWAT from HFD mice.
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this miRNA is increased in PCa compared to normal
tissues [34,38]. Likewise, several reports propose to
hsa-miR-221-3p as a good biomarker for diagnosis,
progression, and response to therapy in PCa
[36,39–41].
Thus, based on our and other groups’ findings, we
propose to hsa-miR-221-3p as a promising miRNA to
be study as a potential biomarker for PCa diagnosis
and prognosis.
In addition to our work, a previous study of Nara
et al. identified 38 up- and 21 downregulated miRNAs
in an androgen-sensitive PCa model (LNCaP xeno-
grafts) under HFD conditions using microRNA
arrays. Specifically, miR-130a was attenuated in HFD-
induced PCa progression and modulated MET expres-
sion in PCa cells [42]. Therefore, the alteration of miR-
NAs in prostate tumors in a HFD environment could
favor PCa development and progression.
Fig. 4. Crosstalk between gWAT and prostate tumor cells by miRNAs released in a MeS environment. (A) Volcano plot representation of DE
miRNAs. Colors indicate the levels of significance. The names of some of the most significant miRNAs are indicated. (B) Heat map
representation of DE miRNAs. Arrows indicate the four miRNAs common to the 10 selected miRNAs based on the literature. (C) Box plots
of the expression of the four selected miRNAs.
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In this work, we conducted a miRNA microarray
analysis with miRNAs obtained from the coculture
medium between TRAMP-C1 cells with HFD-gWAT
versus TRAMP-C1 cells with CD-gWAT. The analysis
revealed 57 increased and 64 decreased miRNAs in
coculture medium of HFD compared with CD group.
When we compared the controlled pathways by the 66
most deregulated miRNAs differentially released, we
found target genes of both, down- and upmodulated
miRNAs, regulated pathways related to fatty acid
metabolism, ER protein processing, amino acid degra-
dation, PI3K/AKT signaling, and PCa. Therefore,
miRNAs release to the coculture medium would mod-
ulate a large plethora of genes that regulates specific
metabolic and cancer-related pathways.
Assuming that miRNAs regulate gene expression by
silencing RNA of their target genes, the decrease in
miRNAs released into the circulating medium, whose
targets are genes of the cell cycle, and/or pathways
related to cancer, may favor the deregulation of these
genes, promoting tumor growth.
It is worth to note the paradoxical expression pat-
tern of some miRNAs between PCa cells, gWAT, and
coculture medium. For instance, while mmu-miR-125-
5p levels do not differ in gWAT neither in TRAMP-
C1 cells from HFD compared to CD mice in cocul-
tures, it was found to be downregulated in the cocul-
ture media of HFD-gWAT/TRAMP-C1 cells
compared to CD-gWAT/TRAMP-C1 using microar-
rays. It is important to mention that we were not able
to detect this miRNA by RT–qPCR in the coculture
media; therefore, these results should be taken with
caution. Differences in methods applied in cells,
gWAT (PCR), and culture medium (microarrays) may
Fig. 5. Functional enrichment analysis of validated miRNA targets. (A, B) Barplot representation of the top significant KEGG pathways
associated with the target genes of the downmodulated (A) and upmodulated (B) miRNAs, released to the medium of the coculture of
TRAMP-C1 cells with gWAT from HFD-fed mice compared to CD-fed mice. The terms common to both groups are indicated in black, and
those specific to each group are highlighted in color. (C, D) Functional enrichment analysis represented as nonredundant biological terms in
a functionally grouped network of miRNA targets exclusive of the downmodulated (C) and upmodulated miRNAs (D).
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Fig. 6. Differential miRNA expression in tumor tissue and circulation of PCa patients. (A) Circulating miRNA expression levels of hsa-miR-
221-3p, 27a-3p, 34a-5p, 155-5p, 138-5p, 146a-5p, 196a-5p, 143-3p, 125b-5p, and 140-5p in plasma of PCa and non-PCa patient samples.
Log2Intensities values are plotted. Data were analyzed by one-way ANOVA. (B) Expression levels of hsa-miR-221-3p, 27a-3p, 34a-5p, 155-
5p, 146a-5p, 196aa-5p, 143-3p, 125b-5p, and 140-5p in prostate primary solid tumor and NAT. Read per millions values are graphed. Data
were analyzed using paired t-test.
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explain in part this inconsistency. More studies are
necessary to understand the scope of these findings
and the source of all the released miRNAs.
In summary, our findings show for the first time a
group of five miRNAs (mmu-miR-221-3p, 27a-3p,
34a-5p, 138-5p, and 146a-5p) as important players
involved in the interaction between WAT and PCa in
MeS mice. From these, hsa-miR-221-3p, 27a-3p, 34a-
5p, and 146a-5p were confirmed to be important in
PCa patients. Further research will be necessary to
track these miRNAs in the interaction between these
































































Fig. 7. Hypothetical model. Upper panel: ex vivo cocultures between TRAMP-C1 cells and adipose tissue from CD- or HFD-fed mice.
miRNAs induced (red arrow) or decreased (green arrow) in the cells, gWAT, and media when compared CD versus HFD groups are listed.
Lower panel: miRNAs up- (red arrow) or downregulated (green arrow) in the postmortem adipose tissue, plasma, and allografts from CD- or
HFD-fed mice.
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5. Conclusions
Our study describes for the first time a signature of 5
miRNAs (mmu-miR-221-3p, 27a-3p, 34a-5p, 138-5p,
and 146a-5p) as important players involved in the
interaction between WAT and PCa in MeS mice.
Moreover, four of these miRNAs were confirmed to
be important in PCa patients.
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